Business
Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim
Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced that it has entered into an exclusive distribution agreement with Er-Kim İlaç Sanayi ve Ticaret A.Ş. ("Er-Kim"), a leading pharmaceutical distributor based in Turkey, for LYMPHIR (denileukin diftitox-cxdl), a novel IL-2 receptor-directed cytotoxin, approved by the U.S. Food and Drug Administration (FDA) for the treatment of ad
About this update from Citius Oncology, Inc.
[{"type":"text","content":"Partnership expands access to LYMPHIR for patients with cutaneous T-cell lymphoma across Turkey, Bahrain, Qatar, Oman, Kuwait, Saudi Arabia, and the UAE","length":152,"tagName":"p","attribs":{}},{"type":"text","content":"LYMPHIR international availability extends to 19 markets outside the U.S.","length":73,"tagName":"p","attribs":{}},{"type":"text","content":"CRANFORD, N.J., Dec. 4, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced that it has entered into an exclusive distribution agreement with Er-Kim İlaç Sanayi ve Ticaret A.Ş. ("Er-Kim"), a leading pharmaceutical distributor based in Turkey, for LYMPHIR (denileukin diftitox-cxdl), a novel IL-2 receptor-directed cytotoxin, approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma after at least one prior systemic therapy. Under the terms of the agreement, Er-Kim will be the exclusive distributor of LYMPHIR in Turkey and key Gulf Cooperation Council (GCC) countries, including Bahrain, Qatar, Oman, Kuwait, Saudi Arabia, and the United Arab Emirates.","length":926,"tagName":"p"},{"type":"image","alt":"Citius Oncology logo (PRNewsfoto/Citius Oncology, Inc.)","displaySize":"","headline":null,"caption":"Citius Oncology logo (PRNewsfoto/Citius Oncology, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":357,"height":400,"url":"https://media.zenfs.com/en/prnewswire.com/92b6ee873ab0a518804912f9102afc89"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Pxr3zuoo.cNFSWXC_5BD3A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTc5MDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/92b6ee873ab0a518804912f9102afc89","width":357,"height":400}},"href":"https://mma.prnewswire.com/media/2588198/Citius_Oncology_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"The agreement expands Citius Oncology's international strategy to a total of 19 markets outside the U.S. leveraging Named Patient Programs. These programs provide access, where permitted by local law, and do not constitute commercial approval of LYMPHIR outside the United States. In October 2025, Citius Oncology announc...